Major depressive disorder, recurrent episode

Also known as: Treatment-resistant Depression / Depression NOS / Major depressive illness / Major depression / Major depressive disorder NOS / Depressive Disorder, Major / Major depressive disorder, recurrent episode, unspecified degree

DrugDrug NameDrug Description
DB00334OlanzapineOlanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.
DrugDrug NameTargetType
DB00334OlanzapineMuscarinic acetylcholine receptor M5target
DB00334OlanzapineD(1A) dopamine receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M1target
DB00334OlanzapineMuscarinic acetylcholine receptor M3target
DB00334Olanzapine5-hydroxytryptamine receptor 2Atarget
DB00334OlanzapineD(4) dopamine receptortarget
DB00334OlanzapineHistamine H1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M4target
DB00334OlanzapineMuscarinic acetylcholine receptor M2target
DB00334OlanzapineD(2) dopamine receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 2Ctarget
DB00334OlanzapineD(3) dopamine receptortarget
DB00334OlanzapineAlpha-1B adrenergic receptortarget
DB00334OlanzapineCytochrome P450 1A2enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 1Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 1Btarget
DB00334Olanzapine5-hydroxytryptamine receptor 1Dtarget
DB00334Olanzapine5-hydroxytryptamine receptor 1Etarget
DB00334Olanzapine5-hydroxytryptamine receptor 3Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 6target
DB00334Olanzapine5-hydroxytryptamine receptor 7target
DB00334OlanzapineAlpha-1A adrenergic receptortarget
DB00334OlanzapineAlpha-2A adrenergic receptortarget
DB00334OlanzapineAlpha-2B adrenergic receptortarget
DB00334OlanzapineAlpha-2C adrenergic receptortarget
DB00334OlanzapineD(1B) dopamine receptortarget
DB00334OlanzapineSerum albumincarrier
DB00334OlanzapineAlpha-1-acid glycoprotein 1carrier
DB00334OlanzapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00334OlanzapineCytochrome P450 2D6enzyme
DB00334OlanzapineMultidrug resistance protein 1transporter
DB00334OlanzapineCytochrome P450 2C19enzyme
DB00334OlanzapineCytochrome P450 3A4enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 2Btarget
DB00334Olanzapine5-hydroxytryptamine receptor 5Atarget
DB00334OlanzapineD(1) dopamine receptortarget
DB00334OlanzapineHistamine H2 receptortarget
DB00334OlanzapineHistamine H4 receptortarget
DB00334OlanzapineGABA-A receptor (anion channel)target
DB00334OlanzapineBeta adrenergic receptortarget
DB00334OlanzapineD(2L) dopamine receptortarget
DB00334OlanzapineD(2S) dopamine receptortarget
DB00334OlanzapineUDP-glucuronosyltransferase 1-1enzyme
DrugDrug NamePhaseStatusCount
DB01221Ketamine2Active Not Recruiting1
DB01221Ketamine2Recruiting1
DB00683Midazolam2Active Not Recruiting1
DB01221Ketamine2 / 3Completed1
DB00683Midazolam2 / 3Completed1
DB00476Duloxetine3Completed5
DB01175Escitalopram3Completed5
DB11823Esketamine3Completed5
DB01104Sertraline3Completed5